newest glp-1 drugs Novo's Wegovy becomes first drug approved for MASH Study predicts 16 new obesity

Genton, Lausanne (Mdecine des voyages)

Wegovy FDA-approved specifically for chronic weight management

Despite production costs being estimated at under $5 per month, the branded pricing creates a substantial financial barrier, especially for patients requiring chronic therapy

Supplementary Information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material

Specific subtypes assessed included Alzheimers disease, vascular dementia, frontotemporal dementia, Parkinsons disease, extrapyramidal and movement disorders, and dementia with Lewy bodies

The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-/-) and LDLr(-/-) mice by a mechanism that includes inflammatory pathways